emibetuzumab
mAbexperimental
Emibetuzumab (INN) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC — Wikipedia
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 13, 2010 (NCT01287546)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEmibetuzumab ↗
- ChEMBLCHEMBL3301578 ↗
- ChEMBLCHEMBL2109517 ↗
Also known as
- emibetuzumab
- emibetuzumab
- ly2875358
- ly-2875358
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02082210 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | Eli Lilly |
| NCT01874938 | Phase 2 | Aug 1, 2013 | Eli Lilly |
| NCT01897480 | Phase 2 | Aug 1, 2013 | Eli Lilly |
| NCT01900652 | Phase 2 | Aug 1, 2013 | Eli Lilly |
| NCT01602289 | Phase 1 | Jun 1, 2012 | Eli Lilly |
| NCT01287546 | Phase 1 | Apr 13, 2010 | Eli Lilly |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 6 | 6 | 2 | 2010 |
1 organizations
Page 1 / 1